April 17th 2024
A new drug called belantamab mafodotin significantly improved survival in relapsed multiple myeloma patients compared to a standard treatment.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Elranatamab Shows Efficacy of BCMA-Targeted Therapy in Multiple Myeloma
January 18th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Mansi R. Shah, MD, discussed the impact of the MagnetisMM-1 and MagnetisMM-3 trials of elranatamab in patients with relapsed/refractory multiple myeloma. This is the second of 2 articles based on this event.
Read More
Quadruplet Trials Form New Standard in Transplant-Eligible Multiple Myeloma
January 9th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Susan Bal, MD, discussed the ongoing significance of the GRIFFIN and MASTER trials in patients with newly diagnosed multiple myeloma, as well as the phase 3 Perseus trial. This is the second of 2 articles based on this event.
Read More
Isatuximab-Based Triplet Therapy Improves Outcomes in R/R Multiple Myeloma
January 4th 2024In the first article of a 2-part series, Douglas Sborov, MD, discusses how the efficacy results of the IKEMA trial not only show isatuximab, carfilzomib, and dexamethasone as a viable treatment option for patients with multiple myeloma, but as further proof triplet therapy is superior to doublet therapy in this patient population.
Read More
Teclistamab Shows Strong Efficacy in Triple-Refractory Multiple Myeloma
December 27th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Mansi R. Shah, MD, discussed the impact of the MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma. This is the first of 2 articles based on this event.
Read More
Selinexor-Based Triplet Shows Tolerability With Dose Reductions in RRMM
December 20th 2023In the second article of a 2-part series, Sumit Madan, MD, talked about the manageable toxicity profile with the triplet therapy selinexor (Xpovio), bortezomib, and dexamethasone and how dose reductions led to tolerable outcomes in patients with relapsed/refractory multiple myeloma.
Read More